Structure-based drug discovery and protein targets in the CNS

Neuropharmacology

Volumn 60, Issue 1, 2011, Pages 7-23

  Hubbard, Roderick E ^a,b  

^a Vernalis PLC   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Fragment based drug discovery; Protein structure; Protein ligand interactions; Structure based drug discovery

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA INTERFERON RECEPTOR; AMPA RECEPTOR; BRADYKININ B2 RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CALCIUM CHANNEL L TYPE; CENTRAL NERVOUS SYSTEM AGENTS; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; DOPAMINE BETA MONOOXYGENASE; DOPAMINE RECEPTOR; ENDOTHELIN A RECEPTOR; G PROTEIN COUPLED RECEPTOR; GALANIN RECEPTOR 3; GAMMA SECRETASE; GLYCINE TRANSPORTER 1; GROWTH HORMONE RELEASING FACTOR RECEPTOR; METABOTROPIC RECEPTOR 5; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROKININ 1 RECEPTOR; NEUROKININ 2 RECEPTOR; OREXIN 1 RECEPTOR; SIALIDASE; SIGMA 1 OPIATE RECEPTOR; SODIUM CHANNEL; TROPONIN; VANILLOID RECEPTOR 1; VERY LATE ACTIVATION ANTIGEN 4; VOLTAGE GATED POTASSIUM CHANNEL;

BINDING AFFINITY; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG RECEPTOR BINDING; DRUG TARGETING; ISOTHERMAL TITRATION CALORIMETRY; LIGAND BINDING; MOLECULAR DOCKING; NEUROPHARMACOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; STEADY STATE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY;

CENTRAL NERVOUS SYSTEM; DRUG DESIGN; DRUG DISCOVERY; LIGANDS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78149501220     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.07.016     Document Type: Review

References (127)

1. Albert J.S., Blomberg N., Breeze A.L., Brown A.J.H., Burrows J.N., Edwards P.D., Folmer R.H.A., Geschwindner S., Griffen E.J., Kenny P.W., Nowak T., Olsson L.-L., Sanganee H., Shapiro A.B. An integrated approach to fragment based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. Curr. Top. Med. Chem. 2007, 7:1600-1629.
2. Arnost M., Pierce A., Haar E.T., Lauffer D., Madden J., Tanner K., Green J. 3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: highly ligand efficient and potent inhibitors of GSK3beta. Bioorg. Med. Chem. Lett. 2010, 20:1661-1664.
3. Aronov A.M., McClain B., Moody C.S., Murcko M.A. Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology. J. Med. Chem. 2008, 51:1214-1222.
4. Aston N.M., Bamborough P., Buckton J.B., Edwards C.D., Holmes D.S., Jones K.L., Patel V.K., Smee P.A., Somers D.O., Vitulli G., Walker A.L. p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression. J. Med. Chem. 2009, 52:6257-6269.
5. Barinka C., Rovenska M., Mlcochova Hlouchova K., Plechanovova A., Majer P., Tsukamoto T., Slusher B.S., Konvalinka J., Lubkowski J. Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J. Med. Chem. 2007, 50:3267-3273.
6. Barr, A.J., Ugochukwu, E., Lee, W.H., King, O.N., Filappakopoulos, P., Alfano, I., Savitsku, P., Burgess-Brown, N.A., Muller, S., Knapp, S., 2009. Large-scale structural analysis of the classical human protein tyrosine phosphatome.
7. Bartesaghi A., Subramaniam S. Membrane protein structure determination using cryo-electron tomography and 3D image averaging. Curr. Opin. Struct. Biol. 2009, 19:402-407.
8. Baurin N., Aboul-Ela F., Barril X., Davis B., Drysdale M., Dymock B., Finch H., Fromont C., Richardson C., Simmonite H., Hubbard R.E. Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets. J. Chem. Inf. Comput. Sci. 2004, 44:2157-2166.
9. Blundell T.L., Jhoti H., Abell C. High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discov. 2002, 1:45-54.
10. Bocquet N., Nury H., Baaden M., Le Poupon C., Changeux J.P., Delarue M., Corringer P.J. X-ray structure of a pentameric ligand-gated ion channel in an apparently open conformation. Nature 2009, 457:111-114.
11. Bohm H.J. The computer program LUDI: a new method for the de novo design of enzyme inhibitors″ J. Comput. Aided Mol. Des. 1992, 6:61-78.
12. Brauchi S., Orta G., Mascayano C., Salazar M., Raddatz N., Urbina H., Rosenmann E., Gonzalez-Nilo F., Latorre R. Dissection of the components for PIP2 activation and thermosensation in TRP channels. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:10246-10251.
13. Brejc K., van Dijk W.J., Klaassen R.V., Schuurmans M., van Der Oost J., Smit A.B., Sixma T.K. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 2001, 411:269-276.
14. Brough P.A., Aherne W., Barril X., Borgognoni J., Boxall K., Cansfield J.E., Cheung K.M., Collins I., Davies N.C., Drysdale M.J., Dymock B., Eccles S.A., Finch H., Fink A., Hayes A., Howes R., Hubbard R.E., James K., Jordan A.M., Lockie A., Martins V., Massey A., Matthews T.P., McDonald E., Northfield C.J., Pearl L.H., Prodromou C., Ray S., Raynaud F.I., Roughley S.D., Sharp S.Y., Surgenor A., Walmsley D.L., Webb P., Wood M., Workman P., Wright L. 4,5-Diarylisoxazole hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J. Med. Chem. 2008, 51:196-218.
15. Brough P.A., Barril X., Borgognoni J., Chene P., Davies N.G.M., Davis B., Drysdale M.J., Dymock B., Eccles S.A., Garcia-Echeverria C., Fromont C., Hayes A., Hubbard R.E., Jordan A.M., Jensen M.R., Massey A., Merrett A., Padfield A., Parsons R., Radimerski T., Raynaud F.I., Robertson A., Roughley S.D., Schoepfer J., Simmonite H., Sharp S.Y., Surgenor A., Valenti M., Walls S., Webb P., Wood M., Workman P., Wright L. Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. J. Med. Chem. 2009, 52:4794-4809.
16. Brzozowski A.M., Pike A.C.W., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.A., Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389:753-758.
17. Burkhard P., Dominici P., Borri-Voltattorni C., Jansonius J.N., Malashkevich V.N. Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase. Nat. Struct. Biol. 2001, 8:963-967.
18. Campagna-Slatera V., Weaver D.F. Molecular modelling of the GABAA ion channel protein. J. Mol. Graph. Model. 2007, 25:721-730.
19. Card G.L., Blasdell L., England B.P., Zhang C., Suzuki Y., Gillette S., Fong D., Ibrahim P.N., Artis D.R., Bollag G., Milburn M.V., Kim S.H., Schlessinger J., Zhang K.Y. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat. Biotechnol. 2005, 23:184-186.
20. Carletti E., Colletier J.P., Dupeux F., Troavslet M., Masson P., Nachon F. Structural evidence that human acetylcholinesterase inhibited by tabun ages through O-dealkylation. J. Med. Chem. 2010, 53:4002-4008.
21. Cavasotto C.N., Phatak S.S. Homology modeling in drug discovery: current trends and applications. Drug Discov. Today 2009, 14:676-683.
22. Chayen N.E., Saridakis E. Protein crystallization: from purified protein to diffraction-quality crystal. Nat. Methods 2008, 5:147-153.
23. Chen I.J., Hubbard R.E. Lessons for fragment library design: analysis of output from multiple screening campaigns. J. Comput. Aided Mol. Des. 2009, 23:603-620.
24. Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., Choi H.J., Kun P., Weiss W.I., Kobilka B.K., Stevens R.C. High resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318:1258-1265.
25. Chico L.K., Van Eldik L.J., Watterson D.M. Targeting protein kinases in central nervous system disorders. Nat. Rev. Drug Discov. 2009, 8:892-909.
26. Colby T.D., Vanderveen K., Strickler M.D., Markham G.D., Goldstein B.M. Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3531-3536.
27. Congreve M., Chessari G., Tisi D., Woodhead A.J. Recent developments in fragment-based drug discovery. J. Med. Chem. 2008, 51:3661-3680.
28. Congreve M., Marshall F. The impact of GPCR structures on pharmacology and structure-based drug design ″ Br. J. Pharmacol. 2010, 159:986-996.
29. Cooper D.R., Boczek T., Grelewska K., Pinkowska M., Sikorska M., Zawadzki M., Derewenda Z. Protein crystallization by surface entropy reduction: optimization of the SER strategy. Acta Cryst. D 2007, 63:636-645.
30. 2-adrenergic receptor. J. Med. Chem. 2008, 51:2907-2914.
31. Cushman D.W., Cheung H.S., Sabo E.F., Ondetti M.A. Design of potent competitive inhibitors of angiotensin-converting enzyme. Caboxyalkonyl and mercaptoalkanoyl amino acids. Biochemistry 1977, 16:5484-5491.
32. Danielson U.H. Fragment library screening and characterization using SPR biosensors. Curr. Top. Med. Chem. 2009, 9:1725-1735.
33. Davies M., Heikkila T., McConkey G.A., Fishwick C.W., Parsons M.R., Johnson A.P. Structure-based design, synthesis and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases. J. Med. Chem. 2009, 52:2683-2693.
34. Davis A.M., St-Gallay S.A., Kleywegt G.J. Limitations and lessons in the use of X-ray structural information in drug design. Drug Discov. Today 2008, 13:831-841.
35. Dellisanti C.D., Yao Y., Stroud J.C., Wang Z.Z., Chen L. Crystal structure of the extracellular domain of nAchR alpha 1 bound to alpha bungarotoxin at 1.94A resolution. Nat. Neurosci. 2007, 10:953-962.
36. Eisen M.B., Wiley D.C., Karplus M., Hubbard R.E. HOOK: a program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site. Proteins Struct. Funct. Genet. 1994, 19:199-221.
37. 2+·calmodulins. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:5135-5140.
38. Federov O., Muller S., Knapp S. The (un)targeted cancer kinome. Nat. Chem. Biol. 2010, 6:166-169.
39. Fink T., Reymond J.-L. Virtual Exploration of the chemical universe up to 11 atoms of C, N, O, F: assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery. J. Chem. Inf. Model. 2007, 47:342-353.
40. Firth-Clark S., Willems H.M., Williams A., Harris W. Generation and selection of novel estrogen receptor ligands using the de novo structure-based design tool, SkelGen. J. Chem. Inf. Model. 2006, 46:642-647.
41. Fischer M., Hubbard R.E. Fragment-based ligand discovery. Mol. Interv. 2009, 9:22-30.
42. Foloppe N., Fisher L.M., Howes R., Potter A., Robertson A.G., Surgenor A.E. Identification of chemically diverse Chk1 inhibitors by receptor-based virtual screening. Bioorg. Med. Chem. 2006, 14:4792-4802.
43. Foloppe N., Hubbard R.E. Towards predictive ligand design with free-energy based computational methods?. Curr. Med. Chem. 2006, 13:3583-3608.
44. Frydenvang K., Lash L.L., Naur P., Postila P.A., Pickering D.S., Smith C.M., Gajhede M., Sasaki M., Sakai R., Pentikainen O.T., Swanson G.T., Kastrup J.S. Full domain closure of the ligand-binding core of the ionotropic glutamate receptor iGluR5 induced by the high affinity agonist dysiherbaine and the functional antagonist 8,9-dideoxyneodysiherbaine. J. Biol. Chem. 2009, 284:14219-14229.
45. Gajiwala K.S., Wu J.C., Christensen J., Deshmukh G.D., Diehl W., DiNitto J.P., English J.M., Grieg M.J., He Y.A., Jacques S.L., Lunney E.A., McTigue M., Molina D., Quenzer T., Wells P.A., Yu X., Zhang Y., Zou A., Emmett M.R., Marshall A.G., Zhang H.M., Demetri G.D. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1542-1547.
46. Gileadi O., Knapp S., Lee W.H., Marsden B.D., Muller S., Niesen F.H., Kavanagh K.L., Ball L.J., von Delft F., Doyle D.A., Oppermann U.C., Sundstrom M. The scientific impact of the structural genomics consortium: a protein family and ligand-centred approach to medically-relevant human proteins. J. Struct. Funct. Genomics 2007, 8:107-119.
47. Goddard W.A., Kim S.K., Li Y.Y., Trzaskowski B., Griffith A.R., Abol R. Predicted 3D structures for adenosine receptors bound to ligands: comparison to the crystal structure. J. Struct. Biol. 2010, 170:10-20.
48. Godemann R., Madden J., Kramer J., Smith M.A., Fritz U., Hesterkamp T., Barker J., Hoeppner S., Hallett D., Cesura A., Ebneth A., Kemp J. Fragment-based discovery of BACE1 inhibitors using functional assays. Biochemistry 2009, 48:10743-10751.
49. Goodford P.J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules″ J. Med. Chem. 1985, 28:849-857.
50. Hajduk P.J. SAR by NMR: putting the pieces together. Mol. Interv. 2006, 6:266-272.
51. Hartshorn M.J., Verdonk M.L., Chessari G., Brewerton S.C., Mooij W.T., Mortenson P.N., Murray C.W. Diverse, high-quality test set for the validation of protein-ligand docking performance. J. Med. Chem. 2007, 50:726-741.
52. Henderson R., Baldwin J.M., Ceska T.A., Zemlin F., Beckmann E., Downing K.H. Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. J. Mol. Biol. 1990, 213:899-929.
53. Hopkins A.L., Groom C.R. The druggable genome. Nat. Rev. Drug Discov. 2002, 1:727-730.
54. Howard S., Berdini V., Boulstridge J.A., Carr M.G., Cross D.M., Curry J., Devine L.A., Early T.R., Fazal L., Gill A.L., Heathcote M., Maman S., Matthews J.E., McMenamin R.L., Navarro E.F., O'Brien M.A., O'Reilly M., Rees D.C., Reule M., Tisi D., Williams G., Vinković M., Wyatt P.G. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J. Med. Chem. 2009, 52:379-388.
55. 2A adenosine receptor bound to an antagonist. Science 2008, 322:1211-1217.
56. Jacobs M., Hayakawa K., Swenson L., Bellon S., Fleming M., Taslimi P., Doran J. The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. J. Biol. Chem. 2006, 281:260-268.
57. Karplus M., Kuriyan J. Molecular dynamics and protein function. Proc. Natl. Acad. Sci. U. S. A. 2006, 102:6679-6685.
58. Karplus M., McCammon J.A. Molecular dynamics simulations of biomolecules. Nat. Struct. Biol. 2002, 9:646-652.
59. Katritch V., Jaakola V.P., Lane J.R., Lin J., Iizerman A.P., Yeager M., Kufareva I., Stevens R.C., Abagyan R. Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J. Med. Chem. 2010, 53:1799-1809.
60. Kendrew J.C., Bodo G., Dintzis H.M., Parrish R.G., Wyckoff H., Phillips D.C. A three-dimensional model of the myoglobin molecular obtained by x-ray analysis. Nature 1958, 181:662-666.
61. Kolb P., Rosenbaum D.M., Irwin J.J., Fung J.J., Kobilka B.K., Shoichet B.K. Structure-based discovery of beta(2)-adrenergic receptor ligands. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:6843-6848.
62. Kreft A.F., Martone R., Porte A. Recent advances in the identification of γ-secretase inhibitors to clinically test the Aβ oligomer hypothesis of Alzheimer's disease. J. Med. Chem. 2009, 52:6169-6188.
63. Krishnamurthy H., Piscitelli C.L., Gouaux E. Unlocking the molecular secrets of sodium-coupled transporters. Nature 2009, 459:347-355.
64. Kurumbail R.G., Stevens A.M., Gierse J.K., McDonald J.J., Stegeman R.A., Pak J.Y., Gildehaus D., Miyashiro J.M., Penning T.D., Seibert K., Isakson P.C., Stallings W.C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996, 384:644-648.
65. Kuyper L.F., Roth B., Baccanari D.P., Ferone R., Beddell C.R., Champness J.N., Stammers D.K., Dann J.G., Norrington F.E., Baker D.J., Goodford P.J. Receptor-based design of dihydrofolate reductase inhibitors: comparison of crystallographically determined enzyme binding with enzyme affinity in a series of carboxy-substituted trimethoprim analogues. J. Med. Chem. 1982, 25:1120-1122.
66. Ladbury J.E., Klebe G., Freire E. Adding calorimetric data to decision making in lead discovery: a hot tip. Nat. Rev. Drug Discov. 2010, 9:23-27.
67. Leach A.R., Shoichet B.K., Peishoff C.E. Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. J. Med. Chem. 2006, 49:5851-5855.
68. Leventhal L., Brandt M.R., Cummons T.A., Piesla M.J., Rogers K.E., Harris H.A. An estrogen receptor-β agonist is active in models of inflammatory and chemical-induced pain. Eur. J. Pharmacol. 2006, 553:146-148.
69. Liu S., Knafels J.D., Chang J.S., Waszak G.A., Baldwin E.T., Deibel M.R., Thomsen D.R., Homa F.L., Wells P.A., Tory M.C., Poorman R.A., Gao H., Qiu X., Seddon A.P. Crystal structure of the herpes simplex virus 1 DNA polymerase. J. Biol. Chem. 2006, 281:18193-18200.
70. Liu X., Xu L., Liu Y., Tong X., Zhu G., Zhang X.C., Li X., Rao Z. Crystal structure of the hexamer of human heat shock factor binding protein. Proteins 2009, 75:1-11.
71. Madauss K.P., Bledsoe R.K., Mclay I., Stewart E.L., Uings I.J., Weingarten G., Williams S.P. The first X-ray crystal structure of the glucocorticoid receptor bound to a non-steroidal agonist. Bioorg. Med. Chem. Lett. 2008, 18:6097-6099.
72. Martinez A., Perez D.I. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?. J. Alzheimer's Dis. 2008, 15:181-191.
73. McLean L.R., Zhang Y., Degnen W., Peppard J., Cabel D., Zou C., Tsay J.T., Subramaniam A., Vaz R.J., Li Y. Discovery of novel inhibitors for DHODH via virtual screening and X-ray crystallographic structures. Bioorg. Med. Chem. Lett. 2010, 20:1981-1984.
74. Michino M., Abola E., GPCR Dock 2008 participants, Brooks C.L., Dixon J.S., Moult J., Stevens R.C. Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008. Nat. Rev. Drug Discov. 2009, 8:455-463.
75. Mileni M., Garfunkle J., Demartino J.K., Cravatt B.F., Boger D.L., Stevens R.C. Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by alpha-ketoheterocycle inhibitors revealed from cocrystal structures. J. Am. Chem. Soc. 2009, 131:10497-10506.
76. Miranker A.D., Karplus M. Functionality maps of binding sites: a multiple copy simultaneous search method. Proteins 1991, 11:29-34.
77. Mooij W.T., Hartshorn M.J., Tickle I.J., Sharff A.J., Verdonk M.L., Jhoti H. Automated protein-ligand crystallography for structure-based drug design. Chem. Med. Chem. 2006, 1:827-838.
78. Morphy R. Selectively nonselective kinase inhibition: striking the right balance. J. Med. Chem. 2010, 53:1413-1437.
79. Morphy R., Rankovic Z. Designing multiple ligands - medicinal chemistry strategies and challenges. Curr. Pharm. Des. 2009, 15:587-600.
80. Murray C.W., Callaghan O., Chessari G., Cleasby A., Congreve M., Frederickson M., Hartshorn M.J., McMenamin R., Patel S., Wallis N. Application of fragment screening by X-ray crystallography to b-secretase. J. Med. Chem. 2007, 50:1116-1123.
81. Muto T., Tsuchiya D., Morikawa K., Jingami H. Structures of the extracellular regions of the group II/III metabotropic glutamate receptors. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:3759-3764.
82. Nakagawa T., Cheng Y., Ramm E., Sheng M., Walz T. Structure and different conformational states of native AMPA receptor complexes. Nature 2005, 433:545-549.
83. Navratilova I., Hopkins A.L. Fragment screening by surface plasmon resonance. ACS Med. Chem. Lett. 2010, 1:44-48.
84. Nienaber V.L., Richardson P.L., Klighofer V., Bouska J.J., Giranda V.L., Greer J. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat. Biotechnol. 2000, 18:1105-1108.
85. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., Saito K., Inoue M., Shirouzu M., Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002, 110:775-787.
86. Overington J.P., Al-Lazikani B., Hopkins A.L. How many drug targets are there?. Nat. Rev. Drug Discov. 2006, 5:993-996.
87. Pantoliano M.W., Petrella E.C., Kwasnoski J.D., Lobanov V.S., Myslik J., Graf E., Carver T., Asel E., Springer B.A., Lane P., Salemme F.R. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J. Biomol. Screen. 2001, 6:429-440.
88. Pellecchia M. Solution nuclear magnetic resonance spectroscopy techniques for probing intermolecular interactions. Chem. Biol. 2005, 12:961-971.
89. Perutz M.F., Lehmann J. Molecular pathology of human haemoglobin. Nature 1968, 219:902-909.
90. Pike A.C.W., Brzozowski A.M., Hubbard R.E. A structural biologist's view of the oestrogen receptor. J. Steroid Biochem. Mol. Biol. 2000, 74:261-268.
91. Pooput C., Rosemond E., Karpiak J., Deflorian F., Vilar S., Costanzi S., Wess J., Kirk K.L. Structural basis of the selectivity of the beta(2)-adrenergic receptor for fluorinated catecholamines. Bioorg. Med. Chem. 2009, 23:7987-7992.
92. Quadt-Akabayov S.R., Chill J.H., Levy R., Kessler N., Anglister J. Determination of the human type I interferon receptor binding site on human interferon-alpha2 by cross saturation and an NMR-based model of the complex. Protein Sci. 2006, 15:2656-2668.
93. Rasmussen S.G., Choi H.J., Rosenbaum D.M., Kobilka T.S., Thian F.S., Edwards P.C., Burghammer M., Ratnala V.R., Sanishvili R., Fischetti R.F., Schertler G.F., Weis W.I., Kobilka B.K. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 2007, 450:383-387.
94. Richardson C.M., Nunns C.L., Williamson D.S., Parratt M.J., Dokurno P., Howes R., Borgognoni J., Drysdale M.J., Finch H., Hubbard R.E., Jackson P.S., Kierstan P., Lentzen G., Moore J.D., Murray J.B., Simmonite H., Surgenor A.E., Torrance C.J. Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping. Biorg. Med. Chem. Lett. 2007, 17:3880-3885.
95. Rimon G., Sidhu R.S., Lauver D.A., Lee J.Y., Sharma N.P., Yuan C., Frieler R.A., Trievel R.C., Lucchesi B.R., Smith W.L. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:28-33.
96. Rosenbaum D.M., Cherezov V., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., Choi H.J., Yao X.J., Weis W.I., Stevens R.C., Kobilka B.K. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 2007, 318:1266-1273.
97. Rosenbaum D.M., Rasmussen S.G.F., Kobilka B.K. The structure and function of G-protein-coupled receptors. Nature 2009, 459:356-363.
98. Russ A.P., Lampel S. The druggable genome: an update. Drug Discov. Today 2005, 10:1607-1610.
99. Scapin G., Patel S.B., Chung C., Varnerin J.P., Edmondson S.D., Mastracchio A., Parmee E.R., Singh S.B., Becker J.W., Van Der Ploeg L.H., Tota M.R. Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity. Biochemistry 2004, 43:6091-6100.
100. Scheer J.M., Romanowski M.J., Wells J.A. A common allosteric site and mechanism in caspases. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7595-7600.
101. Schertler G.F., Villa C., Henderson R. Projection structure of rhodopsin. Nature 1993, 362:770-772.
102. Schneider G. Virtual screening: an endless staircase?. Nat. Rev. Drug Discov. 2010, 9:273-276.
103. Schrer S.C., Brown S.J., Gonzalez-Cabrera P.J., Schaeffer M.-T., Chapman J., Jo E., Chase P., Spicer T., Hodder P., Rosen H. Ligand-binding pocket shape differences between sphingosine 1-phosphate (S1P) receptors S1P1 and S1P3 determine efficiency of chemical probe identification by ultrahigh-throughput screening. ACS Chem. Biol. 2008, 3:486-498.
104. Schulz M., Hubbard R.E. Recent progress in fragment-based discovery. Curr. Opin. Pharmacol. 2009, 9:615-621.
105. Shimamura T., Wayland S., Beckstein O., Rutherford N.G., Hadden J.M., Sharples D., Sansom M.S.P., Iwata S., Henderson P.J.F., Cameron A.D. Molecular basis of alternating access membrane transport by the sodium-hydantoin transporter Mhp1. Science 2010, 328:470-473.
106. Shuker S.B., Hajduk P.J., Meadows R.P., Fesik S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274:1531-1534.
107. Siegal G., Hollander J.G. Target immobilisation and NMR screening of fragments in early drug discovery. Curr. Top. Med. Chem. 2009, 9:1736-1745.
108. Son S.Y., Ma J., Kondou Y., Yoshimura M., Yamashita E., Tsukihara T. Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:5739-5744.
109. Storici P., De Biase D., Bossa F., Bruno S., Mozzarelli A., Peneff C., Silverman R., Schirmer T. Structures of gamma-aminobutyric acid (GABA) aminotransferase, a pyridoxal 5'-phosphate, and [2Fe-2S] cluster-containing enzyme, complexed with gamma-ethynyl-GABA and with the antiepilepsy drug vigabatrin. J. Biol. Chem. 2004, 279:363.
110. Protein production and purification. Nat. Methods 2008, 5:135-146. Structural Genomics Consortium.
111. Taly A., Corringer P.-J., Guedin D., Lestage P., Changeux J.-P. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat. Rev. Drug Discov. 2009, 8:733-750.
112. Tao X., Lee A., Limapichat W., Dougherty D.A., MacKinnon R. A gating charge transfer center in voltage sensors. Science 2010, 328:67-73.
113. Tate C.G., Schertler G.F.X. Engineering G protein-coupled receptors to facilitate their structure determination. Curr. Opin. Struct. Biol. 2009, 19:386-395.
114. Topiol S., Sabio M. X-ray structure breakthroughs in the GPCR transmembrane region. Biochem. Pharmacol. 2009, 78:11-20.
115. Tsuchiya D., Kunishima N., Kamiya N., Jingami H., Morikawa K. Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd3+. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:2660-2665.
116. Tummino P.J., Copeland R.A. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 2008, 47:5481-5492.
117. Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4 Å resolution. J. Mol. Biol. 2005, 346:967-989.
118. Vanwetswinkel S., Heetebrij R.J., van Duvnhoven J., Hollander J.G., Filippov D.V., Hajduk P.J., Siegal G. TINS, target immobilised NMR screening: an efficient and sensitive method for ligand discovery. Chem. Biol. 2005, 12:207-216.
119. Vaughan D., Speed J., Medve R., Andrews J.S. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers. Clin. Ther. 2010, 32:146-160.
120. Verdonk M.L., Mortenson P.N., Hall R.J., Hartshorn M.J., Murray C.W. ″ Protein-ligand docking against non-native protein conformers. J. Chem. Inf. Model. 2008, 48:2214-2225.
121. von Itzstein M., Wu W.-Y., Kok G.B., Pegg M.S., Dyason J.C., Jin B., Phan T.V., Smythe M.L., White H.F., Oliver S.W., Colman P.M., Varghese J.N., Ryan D.M., Woods J.M., Bethell R.C., Hotham V.J., Cameron J.M., Penn C.R. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363:418-423.
122. Warne A., Serrano-Vega M.J., Baker J.G., Moukhametzianov R., Edwards P.C., Henderson R., Leslie A.G.W., Tate C.G., Schertler G.F.X. Structure of the beta1-adrenergic G protein-coupled receptor. Nature 2008, 454:486-491.
123. Warren G.L., Andrews C.W., Cappelli A.-M., Clarke B., LaLonde J., Lambert M.H., Lundvall M., Nevins N., Semus S.F., Senger S., Tedesco G., Wall I.D., Woolven J.M., Peishoff C.E., Head M.S. A critical assessment of docking programs and scoring functions. J. Med. Chem. 2006, 49:5912-5931.
124. Williams S.P., Sigler P.B. Atomic structure of progesterone complexed with its receptor. Nature 1998, 393:392-396.
125. Woodrow M.D., Ballantine S.P., Barker M.D., Clarke B.J., Dawson J., Dean T.W., Delves C.J., Evans B., Gough S.Z., Guntrip S.B., Holman S., Holmes D.S., Kranz M., Lindvaal M.K., Lucas F.S., Neu M., Ranshaw L.E., Solanke Y.E., Somers D.O., Ward P., Wiseman J.O. Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration. Bioorg. Med. Chem. Lett. 2009, 19:5261-5265.
126. Wulff H., Castle N.A., Pardo L.A. Voltage-gated potassium channels as therapeutic targets. Nat. Rev. Drug Discov. 2009, 8:982-1001.
127. Zhou Z.H. Towards atomic resolution structural determination by single-particle cryo-electron microscopy. Curr. Opin. Struct. Biol. 2008, 218-228.